caa a22 4500 469074167 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF01741746 doi (NATIONALLICENCE)springer-10.1007/BF01741746 Enhancement of epidermal growth factor receptor expression on glioma cells by recombinant tumor necrosis factor α [Elektronische Daten] [Koji Adachi, Paul Belser, Hans Bender, Derui Li, Ulrich Rodeck, Etty Benveniste, David Woo, Wolff Schmiegel, Dorothee Herlyn] Summary: Recombinant tumor necrosis factor α (rTNFα; optimal dose 1000 U/ml) significantly increased the density of epidermal growth factor receptor (EGF-R) in three of four glioma cell lines in culture as determined by binding analysis of anti-EGF-R monoclonal antibody (mAb) 425. Since enhancement of EGF-R expression by rTNF-α was inhibited when cells were treated with the protein synthesis inhibitor cycloheximide, the effects of rTNFα may be protein-synthesis-dependent. The dose of rTNFα that was optimal for up-regulation of EGF-R on glioma cells did not inhibit the growth of these cells.125I-labeled mAb 425 lysed glioma cells in culture following its internalization into the cells. After glioma cells had been treated with rTNFα, the growth-inhibitory effects of the mAb were significantly enhanced, probably a reflection of the increase in EGF-R density on the tumor cell surfaces. The rTNFα effects were specific to the EGF-R and did not affect unrelated glioma-associated antigens. In our previous clinical trials,125I-labeled mAb 425 showed immunotherapeutic effects in glioma patients. The present study provides the basis for considerations of combined immunotherapy of glioma patients with125I-labeled mAb 425 and rTNFα. Springer-Verlag, 1992 Epidermal growth factor receptor nationallicence Tumor necrosis factor nationallicence Gliomas nationallicence Adachi Koji The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut Belser Paul The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut Bender Hans The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut Li Derui School of Medicine, Hahnemann University, 19 102, Philadelphia, PA, USA aut Rodeck Ulrich The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut Benveniste Etty University of Alabama at Birmingham, 35 294, Birmingham, AL, USA aut Woo David School of Medicine, Hahnemann University, 19 102, Philadelphia, PA, USA aut Schmiegel Wolff University of Hamburg, Hamburg, Germany aut Herlyn Dorothee The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 34/6(1992-11-01), 370-376 0340-7004 34:6<370 1992 34 262 https://doi.org/10.1007/BF01741746 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741746 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Adachi Koji The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Belser Paul The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Bender Hans The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Li Derui School of Medicine, Hahnemann University, 19 102, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Rodeck Ulrich The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Benveniste Etty University of Alabama at Birmingham, 35 294, Birmingham, AL, USA aut NATIONALLICENCE 700 1- Woo David School of Medicine, Hahnemann University, 19 102, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Schmiegel Wolff University of Hamburg, Hamburg, Germany aut NATIONALLICENCE 700 1- Herlyn Dorothee The Wistar Institute of Anatomy and Biology, 36th and Spruce Streets, 19 104, Philadelphia, PA, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/6(1992-11-01), 370-376 0340-7004 34:6<370 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer